Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies

Advances in Experimental Medicine and Biology

Volumn 750, Issue , 2012, Pages 133-144

  Kwekkeboom, Jaap ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD209 ANTIGEN; CD4 ANTIGEN; FC RECEPTOR IIB; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; T LYMPHOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; AUTOANTIBODY; FC RECEPTOR; LEUKOCYTE ANTIGEN;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL EXPANSION; CELL INTERACTION; CELL MATURATION; DENDRITIC CELL; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; INHIBITION KINETICS; INTRACELLULAR SIGNALING; LYMPHOCYTE DIFFERENTIATION; MOLECULAR INTERACTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; MOUSE; REVIEW;

ANIMALS; ANTIGENS, CD; AUTOANTIBODIES; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE ACTIVATION; MICE; RECEPTORS, FC; T-LYMPHOCYTES, REGULATORY;

EID: 84866783067     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3461-0_10     Document Type: Article

References (62)

1. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-31. PMID:6112565 doi:10.1016/S0140-6736(81)92400-4
2. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-55. PMID:11547745 doi:10.1056/NEJMra993360
3. Negi VS, Elluru S, Siberil S et al. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol 2007; 27:233-45. PMID:17351760 doi:10.1007/s10875-007-9088-9 (Pubitemid 46790823)
4. Tha-In T, Bayry J, Metselaar HJ et al. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29:608-15. PMID:18926775 doi:10.1016/j.it.2008.08.004
5. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: Appropriate indications and uses in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8:117-30. PMID:11939601 doi:10.1053/bbmt.2002.v8. pm11939601 (Pubitemid 34285070)
6. Luke PP, Scantlebury VP, Jordan ML et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72:419-22. PMID:11502969 doi:10.1097/00007890-200108150-00010 (Pubitemid 32769625)
7. Casadei DH, del C Rial M, Opelz G et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71:53-8. PMID:11211195 doi:10.1097/00007890- 200101150-00009
8. Kwekkeboom J, Tha-In T, Tra WM et al. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation. Am J Transplant 2005; 5:2393-402. PMID:16162187 doi:10.1111/j.1600-6143.2005.01029.x
9. Bucuvalas JC, Anand R. Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients. Liver Transpl 2009; 15:1564-9. PMID:19877216 doi:10.1002/lt.21843
10. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 2004; 101:14210-5. PMID:15381781 doi:10.1073/pnas.0402183101 (Pubitemid 39305055)
11. Bayry J, Lacroix-Desmazes S, Hermine O et al. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 2005; 118:1439-40. PMID:16378810 doi:10.1016/j. amjmed.2005.06.028
12. Bayry J, Lacroix-Desmazes S, Kazatchkine MD et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 2004; 104:2441-3. PMID:15226176 doi:10.1182/ blood-2004-04-1325
13. Bayry J, Lacroix-Desmazes S, Carbonneil C et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101:758-65. PMID:12393386 doi:10.1182/blood-2002-05-1447 (Pubitemid 36077604)
14. Bayry J, Lacroix-Desmazes S, Delignat S et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48:3497-502. PMID:14674000 doi:10.1002/art.11346 (Pubitemid 37531915)
15. Tha-In T, Metselaar HJ, Tilanus HW et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 2006; 81:1725-34. PMID:16794540 doi:10.1097/01.tp.0000226073.20185.b1 (Pubitemid 43948307)
16. Smed-Sorensen A, Moll M, Cheng TY et al. IgG regulates the CD1 expression profile and lipid antigen presenting function in human dendritic cells via Fc{gamma}RIIa. Blood 2008; 11:5037-46 PMID:18337560 doi:10.1182/blood-2007-07- 099549.
17. Aubin E, Lemieux R, Bazin R. Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation. Blood 2010; 115:1727-34. PMID:19965673 doi:10.1182/blood-2009-06- 225417
18. Bayry J, Bansal K, Kazatchkine MD et al. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIG on human dendritic cells. Proc Natl Acad Sci U S A. 2009;106:E24; author reply E25.
19. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: Shaping immune responses. Nat Rev Immunol 2009; 9:465-79. PMID:19521399 doi:10.1038/nri2569
20. Requena M, Bouhlal H, Nasreddine N et al. Inhibition of HIV-1 transmission in trans from dendritic cells to CD4+ T lymphocytes by natural antibodies to the CRD domain of DC-SIGN purified from breast milk and intravenous immunoglobulins. Immunology 2008; 123:508-18. PMID:17999675 doi:10.1111/ j.1365-2567.2007.02717.x
21. Geijtenbeek TB, Van Vliet SJ, Koppel EA et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 2003; 197:7-17. PMID:12515809 doi:10.1084/jem.20021229 (Pubitemid 36110253)
22. Gringhuis SI, den Dunnen J, Litjens M et al. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat Immunol 2009; 10:1081-8. PMID:19718030 doi:10.1038/ni.1778
23. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-3. PMID:16888140 doi:10.1126/science.1129594 (Pubitemid 44201145)
24. Anthony RM, Nimmerjahn F, Ashline DJ et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-6. PMID:18420934 doi:10.1126/science.1154315 (Pubitemid 351555659)
25. Anthony RM, Wermeling F, Karlsson MC et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105:19571-8. PMID:19036920 doi:10.1073/ pnas.0810163105
26. Geijtenbeek TB, Groot PC, Nolte MA et al. Marginal zone macrophages express a murine homologue of DC-SIGN that captures blood-borne antigens in vivo. Blood 2002; 100:2908-16. PMID:12351402 doi:10.1182/blood-2002-04-1044
27. Pöhlmann S, Soilleux EJ, Baribaud F et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci USA 2001; 98:2670-5. PMID:11226297 doi:10.1073/pnas.051631398 (Pubitemid 32209540)
28. Anthony RM, Kobayashi T, Wermeling F et al. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475:110-3. PMID:21685887 doi:10.1038/nature10134
29. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-6. PMID:11161202 doi:10.1126/science.291.5503.484 (Pubitemid 32097072)
30. Bruhns P, Samuelsson A, Pollard JW et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18:573-81. PMID:12705859 doi:10.1016/S1074-7613(03)00080-3 (Pubitemid 36513638)
31. Kaneko Y, Nimmerjahn F, Madaio MP et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006; 203:789-97. PMID:16520389 doi:10.1084/jem.20051900
32. Siragam V, Brinc D, Crow AR et al. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005; 115:155-60. PMID:15630455 (Pubitemid 40385516)
33. Siragam V, Crow AR, Brinc D et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12:688-92. PMID:16715090 doi:10.1038/nm1416 (Pubitemid 43865239)
34. Dhodapkar KM, Kaufman JL, Ehlers M et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci USA 2005; 102:2910-5. PMID:15703291 doi:10.1073/pnas.0500014102 (Pubitemid 40299890)
35. Dhodapkar KM, Banerjee D, Connolly J et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J Exp Med 2007; 204:1359-69. PMID:17502666 doi:10.1084/jem.20062545 (Pubitemid 46919874)
36. Boruchov AM, Heller G, Veri MC et al. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 2005; 115:2914-23. PMID:16167082 doi:10.1172/JCI24772 (Pubitemid 41434419)
37. Tackenberg B, Jelcic I, Baerenwaldt A et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci USA 2009; 106:4788-92. PMID:19261857 doi:10.1073/pnas.0807319106
38. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26:513-33. PMID:18370923 doi:10.1146/annurev. immunol.26.021607.090232
39. Huang HS, Sun DS, Lien TS et al. Dendritic cells modulate platelet activity in IVIG-mediated amelioration of ITP in mice. Blood 2010; 116:5002-9. PMID:20699442 doi:10.1182/blood-2010-03-275123
40. Park-Min KH, Serbina NV, Yang W et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26:67-78. PMID:17239631 doi:10.1016/j.immuni.2006.11. 010 (Pubitemid 46127754)
41. van Mirre E, Teeling JL, van der Meer JW et al. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcgammaRII and FcgammaRIIIb. J Immunol 2004; 173:332-9. PMID:15210791 (Pubitemid 38797358)
42. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994; 139:159-72. PMID:7927410 doi:10.1111/j.1600-065X.1994.tb00861.x (Pubitemid 24232676)
43. Vassilev TL, Bineva IL, Dietrich G et al. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun 1995; 8:405-13. PMID:7576001 doi:10.1006/jaut.1995. 0032
44. Tha-In T, Metselaar HJ, Tilanus HW et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 2007; 110:3253-62. PMID:17673603 doi:10.1182/blood-2007-03-077057 (Pubitemid 350106318)
45. Andersson UG, Bjork L, Skansen-Saphir U et al. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79:211-6. PMID:8344700 (Pubitemid 23172214)
46. Amran D, Renz H, Lack G et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180-6. PMID:7523013 doi:10.1006/ clin.1994.1186
47. Modiano JF, Amran D, Lack G et al. Posttranscriptional regulation of T-cell IL-2 production by human pooled immunoglobin. Clin Immunol Immunopathol 1997; 83:77-85. PMID:9073539 doi:10.1006/clin.1997.4329 (Pubitemid 27128399)
48. MacMillan HF, Lee T, Issekutz AC. Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation. Clin Immunol 132:222-33. PMID:19447680 doi:10.1016/j.clim.2009.04.002
49. Marchalonis JJ, Kaymaz H, Dedeoglu F et al. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci USA 1992; 89:3325-9. PMID:1565623 doi:10.1073/ pnas.89.8.3325
50. Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIG). Ther Immunol 1994; 1:269-77. PMID:7584501 (Pubitemid 24344443)
51. Kersh GJ, Allen PM. Structural basis for T cell recognition of altered peptide ligands: A single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med 1996; 184:1259-68. PMID:8879197 doi:10.1084/jem.184.4.1259 (Pubitemid 26354681)
52. Kersh GJ, Allen PM. Essential flexibility in the T-cell recognition of antigen. Nature 1996; 380:495-8. PMID:8606766 doi:10.1038/380495a0 (Pubitemid 26110635)
53. Germain RN, Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 1999; 17:467-522. PMID:10358766 doi:10.1146/ annurev.immunol.17.1.467 (Pubitemid 29241132)
54. Kessel A, Ammuri H, Peri R et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179:5571-5. PMID:17911644
55. Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111:715-22. PMID:17932250 doi:10.1182/blood-2007-03-079947
56. Tha-In T, Metselaar HJ, Bushell AR et al. Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells. Transplantation 2010; 89:1446-55. PMID:20463648 doi:10.1097/TP.0b013e3181dd6bf1
57. Furuno K, Yuge T, Kusuhara K et al. CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr 2004; 145:385-90. PMID:15343196 doi:10.1016/j.jpeds.2004.05.048 (Pubitemid 39165689)
58. Olivito B, Taddio A, Simonini G et al. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010; 28:93-7. PMID:20412712
59. Chi LJ, Wang HB, Zhang Y et al. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol 2007; 192:206-14. PMID:17997492 doi:10.1016/j. jneuroim.2007.09.034
60. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008; 112:3303-11. PMID:18660382 doi:10.1182/blood-2008-02-138073
61. Becker C, Kubach J, Wijdenes J et al. CD4-mediated functional activation of human CD4+CD25+ regulatory T cells. Eur J Immunol 2007; 37:1217-23. PMID:17407195 doi:10.1002/eji.200636480 (Pubitemid 46925306)
62. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 2007; 3:120-1. PMID:17342189 doi:10.1038/ncpneuro0429 (Pubitemid 46403934)